AnaptysBio Announces Second Quarter 2018 Financial Results and Provides Pipeline Updates
Top-line Phase 2a Data from Etokimab (ANB020) in Eosinophilic Asthma Expected in Third Quarter of 2018 Etokimab Clinical Development Program Expanded to Include Chronic Rhinosinusitis with Nasal Polyps Commercial Considerations Led to Deprioritization of …